enGene Holdings Inc. (NASDAQ:ENGN) Receives $26.40 Consensus Price Target from Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has been given a consensus recommendation of “Buy” by the ten analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $25.89.

Several brokerages recently weighed in on ENGN. Citizens Jmp raised enGene to a “strong-buy” rating in a research report on Monday, November 18th. UBS Group lowered enGene from a “buy” rating to a “neutral” rating and cut their price objective for the company from $34.00 to $7.00 in a research report on Friday, February 14th. Piper Sandler initiated coverage on enGene in a research report on Tuesday. They issued an “overweight” rating and a $26.00 price objective on the stock. JMP Securities reissued a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a research report on Monday, December 23rd. Finally, HC Wainwright initiated coverage on enGene in a research report on Monday, December 23rd. They issued a “buy” rating and a $25.00 price objective on the stock.

enGene Trading Up 2.0 %

Shares of ENGN opened at $6.24 on Wednesday. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $276.07 million, a P/E ratio of -10.76 and a beta of -0.65. The stock’s fifty day simple moving average is $6.76 and its 200 day simple moving average is $7.20. enGene has a twelve month low of $4.42 and a twelve month high of $18.40.

enGene (NASDAQ:ENGN) last issued its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.06. On average, equities research analysts forecast that enGene will post -1.56 earnings per share for the current year.

Institutional Trading of enGene

Hedge funds and other institutional investors have recently modified their holdings of the business. Franklin Resources Inc. increased its position in shares of enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after acquiring an additional 389,918 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of enGene by 1,410.3% during the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after acquiring an additional 619,100 shares during the last quarter. Wolverine Asset Management LLC acquired a new position in enGene in the third quarter worth about $37,000. Cubist Systematic Strategies LLC grew its stake in enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock worth $102,000 after purchasing an additional 2,080 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new position in enGene in the fourth quarter worth about $2,460,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.